Reported Earnings • May 14
Second quarter 2026 earnings: EPS and revenues miss analyst expectations Second quarter 2026 results: US$0.25 loss per share (improved from US$0.44 loss in 2Q 2025). Revenue: US$2.39m (up 73% from 2Q 2025). Net loss: US$2.09m (loss narrowed 8.1% from 2Q 2025). Revenue missed analyst estimates by 7.2%. Earnings per share (EPS) also missed analyst estimates by 10%. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 8.0% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Breakeven Date Change • May 13
Forecast to breakeven in 2028 The 3 analysts covering NeuroOne Medical Technologies expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$1.41m in 2028. Average annual earnings growth of 60% is required to achieve expected profit on schedule. Announcement • Apr 30
NeuroOne Medical Technologies Corporation to Report Q2, 2026 Results on May 12, 2026 NeuroOne Medical Technologies Corporation announced that they will report Q2, 2026 results at 9:30 AM, US Eastern Standard Time on May 12, 2026 Announcement • Mar 04
NeuroOne Medical Technologies Corporation announced that it has received CAD 0.6704 million in funding NeuroOne Medical Technologies Corporation announced a private placement of 1,000,000 common shares at a purchase price of $0.6704 per share for gross proceeds of $670,400 on March 3, 2026. The transaction included participation from David Wambeke, Chief Business Officer. Price Target Changed • Mar 02
Price target decreased by 8.6% to US$2.03 Down from US$2.23, the current price target is an average from 3 analysts. New target price is 205% above last closing price of US$0.67. Stock is down 38% over the past year. The company is forecast to post a net loss per share of US$0.12 next year compared to a net loss per share of US$0.09 last year. Announcement • Feb 26
NeuroOne Medical Technologies Corporation, Annual General Meeting, Apr 03, 2026 NeuroOne Medical Technologies Corporation, Annual General Meeting, Apr 03, 2026. New Risk • Feb 18
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$6.3m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$6.3m free cash flow). Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$4.8m net loss in 2 years). Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (US$41.0m market cap). Reported Earnings • Feb 18
First quarter 2026 earnings: EPS and revenues exceed analyst expectations First quarter 2026 results: US$0.029 loss per share (down from US$0.058 profit in 1Q 2025). Revenue: US$2.89m (down 12% from 1Q 2025). Net loss: US$1.44m (down 181% from profit in 1Q 2025). Revenue exceeded analyst estimates by 8.8%. Earnings per share (EPS) also surpassed analyst estimates by 25%. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings. Announcement • Feb 06
NeuroOne Medical Technologies Corporation to Report Q1, 2026 Results on Feb 17, 2026 NeuroOne Medical Technologies Corporation announced that they will report Q1, 2026 results Pre-Market on Feb 17, 2026 New Risk • Jan 03
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$1.4m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (US$38.2m market cap). Major Estimate Revision • Dec 31
Consensus revenue estimates increase by 11% The consensus outlook for revenues in fiscal year 2026 has improved. 2026 revenue forecast increased from US$10.1m to US$11.3m. Forecast losses expected to reduce from -US$0.17 to -US$0.155 per share. Medical Equipment industry in the US expected to see average net income growth of 16% next year. Consensus price target up from US$2.23 to US$2.30. Share price was steady at US$0.72 over the past week. Reported Earnings • Dec 19
Full year 2025 earnings: EPS and revenues exceed analyst expectations Full year 2025 results: US$0.09 loss per share (improved from US$0.46 loss in FY 2024). Revenue: US$12.1m (up 250% from FY 2024). Net loss: US$3.61m (loss narrowed 71% from FY 2024). Revenue exceeded analyst estimates by 2.2%. Earnings per share (EPS) also surpassed analyst estimates by 22%. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 8.4% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings. Announcement • Dec 13
NeuroOne Medical Technologies Corporation to Report Q4, 2025 Results on Dec 17, 2025 NeuroOne Medical Technologies Corporation announced that they will report Q4, 2025 results Pre-Market on Dec 17, 2025 New Risk • Nov 11
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 12% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 12% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (62% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$6.5m net loss in 2 years). Market cap is less than US$100m (US$34.7m market cap). Announcement • Nov 05
Nasdaq Grants 180-Day Extension Period to Neuroone Medical to Regain Compliance On November 4, 2025, NeuroOne Medical Technologies Corporation (the Company") received a letter (the Extension Notice") from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC (Nasdaq") notifying the Company that Nasdaq has granted the Company a 180-day extension, until May 4, 2026 (the Extension Period"), to regain compliance with the requirement for the Company's common stock, par value $0.001 per share (Common Stock"), to maintain a minimum bid price of $1.00 per share for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the Minimum Bid Price Requirement"). The Extension Notice has no immediate effect on the continued listing status of the Company's Common Stock on the Nasdaq Capital Market. The Company's listing on the Nasdaq Capital Market remains fully effective. As previously disclosed in the Company's Current Report on Form 8-K, filed on May 9, 2025, the Company received notice from Nasdaq that the Company was not in compliance with the Minimum Bid Price Requirement for a period of 30 consecutive business days (the Initial Notice"). As provided in the Initial Notice, the Company had a180-day period, until November 3, 2025, to regain compliance with the Minimum Bid Price Requirement. As of the date of this Report, the Company has not yet regained compliance with the Minimum Bid Price Requirement, and instead advised Nasdaq of its intent to cure the deficiency within the Extension Period. The Company will continue to monitor the closing bid price of its Common Stock and seek to regain compliance with the Minimum Bid Price Requirement within the Extension Period. If the Company does not regain compliance with the Minimum Bid Price Requirement within the Extension Period, Nasdaq will provide written notification to the Company that its Common Stock will be subject to delisting, at which time the Company may appeal Nasdaq's delisting determination to a Nasdaq Hearing Panel (the Panel"). There can be no assurance that, if the Company does need to appeal a Nasdaq delisting determination to the Panel, that such appeal would be successful. Announcement • Aug 19
NeuroOne Medical Technologies Corporation Receives FDA 510(K) Clearance for OneRF ®? Trigeminal Nerve Ablation System to Treat Facial Pain NeuroOne Medical Technologies Corporation has received U.S. Food and Drug Administration clearance to market its OneRF Trigeminal Nerve Ablation System for use in procedures to create radiofrequency lesions for the treatment of pain, or for lesioning nerve tissue for functional neurosurgical procedures. As previously announced, the company completed the FDA submission earlier than anticipated and now targets a limited commercial launch in the fourth quarter of calendar 2025. This clearance leverages the Company's proprietary OneRF®? Ablation System RF generator platform for the treatment of trigeminal neuralgia, a chronic pain condition affecting approximately 150,000 people in the United States annually. The trigeminal nerve is the main sensory nerve in the face associated with triggering extraordinary pain for this condition. Trigeminal neuralgia is typically treated with medication or invasive procedures, including microvascular compression (MVD), radiosurgery, or other percutaneous techniques. The OneRF®? Trigeminal Nerve ABlation System features a minimally invasive surgical technology to treat severe, chronic facial pain. The system delivers targeted radiofrequency (RF) energy to ablate trigeminal nerve fibers, interrupting pain signaling. Differentiated features of this system include a first-of-its-kind multi-contact RF probe that allows for both precise localization and tailored ablation of the pain-conducting nerve tissue - using the same RF probe, and under temperature-controlled conditions which enhance safety and accuracy. This system may allow for reduced procedural time, improved patient comfort and improved patient safety. Reported Earnings • Aug 15
Second quarter 2025 earnings released: US$0.073 loss per share (vs US$0.11 loss in 2Q 2024) Second quarter 2025 results: US$0.073 loss per share (improved from US$0.11 loss in 2Q 2024). Revenue: US$1.39m (flat on 2Q 2024). Net loss: US$2.27m (loss narrowed 21% from 2Q 2024). Revenue is forecast to grow 36% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings. New Risk • Aug 15
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (62% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$4.5m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (US$41.4m market cap). Announcement • Jul 31
NeuroOne Medical Technologies Corporation to Report Q3, 2025 Results on Aug 14, 2025 NeuroOne Medical Technologies Corporation announced that they will report Q3, 2025 results Pre-Market on Aug 14, 2025 Announcement • Jul 24
NeuroOne Medical Technologies Corporation Receives Notice of Allowance for Key Patent from U.S. Patent & Trademark Office NeuroOne Medical Technologies Corporation has received a notice of allowance for a key patent from the U.S. Patent and Trademark Office (USPTO) titled, "Methods for Making Probe Devices and Related Devices". The U.S. Patent Application 17/392,773 is strategic in nature and covers novel methods of making neural probe devices, including specific steps for the arrangement of probe components and deposition of electrode contact material. A Notice of Allowance is issued by the USPTO after examination of a patent application and a determination that a patent should be granted from the application. NeuroOne anticipates the issuance of the patent in the coming months. In addition to this allowed patent application, NeuroOne's patent portfolio includes 17 issued and pending patents in the United States and internationally, covering a wide variety of thin-film electrode technologies. Among these include both neural and spinal cord electrodes with unique structures to optimize the functionality and minimize the profile of those electrodes. Announcement • Jun 04
NeuroOne Medical Technologies Corporation Appoints Emily Johns as General Counsel and Corporate Secretary NeuroOne Medical Technologies Corporation announced the appointment of Emily Johns as General Counsel and Corporate Secretary. Ms. Johns is an experienced public company lawyer who most recently served as a partner at Honigman LLP, where she represented many biotechnology companies in securities and corporate governance matters, including representing NeuroOne on all transactional work since 2017. Previously, she began her career at Sullivan & Cromwell LLP, where she represented public companies in securities offerings and merger transactions. She received her J.D. from UCLA School of Law and her bachelor's degree from the University of Michigan. Announcement • May 15
NeuroOne Medical Technologies Corporation Re-Affirms Earnings Guidance for the Full Year 2025 NeuroOne Medical Technologies Corporation re-affirmed earnings guidance for the full year 2025. The company expects product revenue for fiscal year 2025 to range between $8.0 million and $10.0 million, representing an increase of between 132% and 190% when compared to product revenue of $3.5 million in fiscal year 2024. Reported Earnings • May 14
Second quarter 2025 earnings: EPS and revenues exceed analyst expectations Second quarter 2025 results: US$0.073 loss per share (improved from US$0.11 loss in 2Q 2024). Revenue: US$1.39m (flat on 2Q 2024). Net loss: US$2.27m (loss narrowed 21% from 2Q 2024). Revenue exceeded analyst estimates by 9.2%. Earnings per share (EPS) also surpassed analyst estimates by 22%. Revenue is forecast to grow 36% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Announcement • May 13
Neuroone Medical Technologies Corporation Appoints Dr. Parag Patil as Chief Medical Advisor NeuroOne Medical Technologies Corporation announced it has appointed Parag G. Patil, M.D., Ph.D., as Chief Medical Advisor (CMA), after serving on the company’s Scientific Advisory Board since 2018. Dr. Parag G. Patil is a neurosurgeon-engineer with 20 years’ experience serving patients and advancing innovative therapies to alleviate neurological disorders. After joining the faculty at the University of Michigan in 2005, he has served as an Associate Professor of Neurosurgery, Neurology, Anesthesiology, and Biomedical Engineering. He additionally serves as Associate Chair for Clinical and Translational Research and in leadership roles in diverse multi-disciplinary, multi-investigator research efforts and national societies. His academic goal is to utilize engineering and mathematical techniques, along with interdisciplinary collaboration, to improve neuroprosthetics and perform translational neuroscience research. His NIH and NSF-funded research focuses on electrophysiology, imaging, mathematical modeling, and the development of improved therapies for the treatment of paralysis, pain, and movement disorders using neural-interface devices. Dr. Patil received a B.S. in electrical engineering from the Massachusetts Institute of Technology. After graduation, he was awarded a Marshall Scholarship to study Philosophy and Economics at Magdalen College, Oxford University in the UK. On returning to the U.S., Dr. Patil pursued combined medical and doctoral studies in biomedical engineering at Johns Hopkins University, followed by a neurosurgery residency at Duke University and a fellowship at the University of Toronto. Announcement • May 10
NeuroOne Medical Technologies Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market On May 6, 2025, NeuroOne Medical Technologies Corporation received a letter from the Listing Qualifications Department of the Nasdaq Stock Market notifying the Company that because the closing bid price of the Company’s common stock was below $1.00 per share for the prior 30 consecutive business days, the Company is not in compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market, as set in Nasdaq Marketplace Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). In accordance with Nasdaq Marketplace Rule 5810(c)(3)(A), the Company has a period of 180 calendar days from May 6, 2025, or until November 3, 2025, to regain compliance with the Minimum Bid Price Requirement. If at any time before November 3, 2025, the closing bid price of the Company’s common stock closes at or above $1.00 per share for a minimum of 10 consecutive business days (which number days may be extended by Nasdaq), Nasdaq will provide written notification that the Company has achieved compliance with the Minimum Bid Price Requirement, and the matter would be resolved. The Notice also disclosed that in the event the Company does not regain compliance with the Rule by November 3, 2025, the Company may be eligible for additional time. To qualify for additional time, the Company would be required to meet the applicable market value of publicly held shares requirement for continued listing and all other applicable standards for initial listing on The Nasdaq Capital Market, with the exception of the bid price requirement, and would need to provide written notice of its intention to cure the deficiency during the second compliance period. If the Company meets these requirements, Nasdaq will inform the Company that it has been granted an additional 180 calendar days. However, if it appears to the Staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice that the Company’s securities will be subject to delisting. The Company intends to continue actively monitoring the closing bid price for the Company’s common stock between now and November 3, 2025, and will consider available options to resolve the deficiency and regain compliance with the Minimum Bid Price Requirement. If the Company does not regain compliance within the allotted compliance period, including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company’s common stock will be subject to delisting. The Company would then be entitled to appeal that determination to a Nasdaq hearings panel. There can be no assurance that the Company will regain compliance with the Minimum Bid Price Requirement during the 180-day compliance period, secure a second period of 180 calendar days to regain compliance, or maintain compliance with the other Nasdaq listing requirements. Announcement • May 01
NeuroOne Medical Technologies Corporation to Report Q2, 2025 Results on May 13, 2025 NeuroOne Medical Technologies Corporation announced that they will report Q2, 2025 results Pre-Market on May 13, 2025 Announcement • Apr 23
NeuroOne® Completes FDA Submission for the OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain NeuroOne Medical Technologies Corporation has filed its 510(k) submission to the FDA for trigeminal nerve ablation earlier than previous guidance. This submission leverages the Company's proprietary OneRF®? Ablation System RF generator platform for the treatment of trigeminal neuralgia, a chronic pain condition affecting approximately 100,000 people in the U.S.1. The trigeminal nerve is the main sensory nerve in the face associated with triggering excruciating pain for this condition. Trigeminal neuralgia is typically treated with medication or invasive procedures, including microvascular decompression (MCD), radiosurgery, or other percutaneous techniques. The OneRF®? Trigeminal Nerve Ablation technology features a minimally invasive surgical procedure that uses radiofrequency (RF) energy to destroy abnormal tissue to relieve severe, chronic pain in the face. Differentiated features of this multi-contact probe are designed to use multi-point mapping of pain location, stimulation and ablation, all using the same electrode and with the safety of temperature-controlled ablation. These features are also present in the FDA 510(k) cleared OneRF sEEG (brain) Ablation System. This system may allow for reduced procedural time, improved patient comfort and improved patient safety. Previously published data have shown that RF ablation offers high initial pain relief rates (~95%) and long-term efficacy, especially with repeat treatments, while maintaining a low complication rate. These characteristics make it a preferred option for patients who are not candidates for major surgery or who are looking for less invasive approaches. New Risk • Apr 09
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 83% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (83% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Market cap is less than US$100m (US$20.8m market cap). Recent Insider Transactions • Apr 09
Chief Financial Officer recently bought US$100k worth of stock On the 4th of April, Ronald McClurg bought around 200k shares on-market at roughly US$0.50 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Ronald's only on-market trade for the last 12 months. Announcement • Apr 05
NeuroOne Medical Technologies Corporation has completed a Follow-on Equity Offering in the amount of $8 million. NeuroOne Medical Technologies Corporation has completed a Follow-on Equity Offering in the amount of $8 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 16,000,000
Price\Range: $0.5
Discount Per Security: $0.035 New Risk • Apr 04
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Shareholders have been diluted in the past year (19% increase in shares outstanding). Market cap is less than US$100m (US$26.5m market cap). Announcement • Apr 04
NeuroOne Medical Technologies Corporation has filed a Follow-on Equity Offering. NeuroOne Medical Technologies Corporation has filed a Follow-on Equity Offering.
Security Name: Common Stock
Security Type: Common Stock Announcement • Mar 11
NeuroOne Medical Technologies Corporation Accelerates Timeline of 510(K) Submission to FDA for the OneRF Trigeminal Nerve Ablation System to Treat Facial Pain NeuroOne Medical Technologies Corporation has accelerated the anticipated timeline of its 510(k) submission to the FDA for trigeminal nerve ablation to May 2025, which leverages the Company's patented OneRF Technology Platform. The Company had previously projected a submission by the end of June 2025. Trigeminal nerve ablation is a minimally invasive surgical procedure that uses radiofrequency (RF) energy to destroy abnormal tissue to relieve severe, chronic pain in the face caused by trigeminal neuralgia. The trigeminal nerve is the main sensory nerve in the face and NeuroOne's procedure is designed to provide pain relief for this condition. According to the October 2024 Research and Markets report titled Trigeminal Neuralgia Therapeutics Market, the trigeminal neuralgia therapeutics market, comprised of pharmacologic and surgical technologies, is expected to grow from $262 million in 2024 to over $416 million by 2030, primarily due to anaging population. Announcement • Feb 15
NeuroOne Medical Technologies Corporation Re-Affirms Earnings Guidance for the Full Year 2025 NeuroOne Medical Technologies Corporation re-affirmed earnings guidance for the full year 2025. The company expects product revenue for fiscal year 2025 to range between $8.0 million and $10.0 million, representing an increase of between 132% and 190% when compared to product revenue of $3.5 million in fiscal year 2024. Reported Earnings • Feb 13
First quarter 2025 earnings released: EPS: US$0.058 (vs US$0.14 loss in 1Q 2024) First quarter 2025 results: EPS: US$0.058 (up from US$0.14 loss in 1Q 2024). Revenue: US$3.27m (up 235% from 1Q 2024). Net income: US$1.79m (up US$5.13m from 1Q 2024). Profit margin: 55% (up from net loss in 1Q 2024). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings. Announcement • Feb 05
NeuroOne Medical Technologies Corporation to Report Q1, 2025 Results on Feb 12, 2025 NeuroOne Medical Technologies Corporation announced that they will report Q1, 2025 results Pre-Market on Feb 12, 2025 Announcement • Jan 11
NeuroOne Medical Technologies Provides Nasdaq Non-Compliance Update Regarding Minimum Bid Price Requirement As previously reported, on July 11, 2024, NeuroOne Medical Technologies Corporation (the Company") received a letter (the Bid Price Deficiency Notice") from the Listing Qualifications Department (the Staff") of the Nasdaq Stock Market (Nasdaq") notifying the Company that, because the closing bid price for its common stock had been below $1.00 per share for 30 consecutive trading days, it was not compliant with Nasdaq Marketplace Rule 5550(a)(2) (the Minimum Bid Price Requirement"). In accordance with Nasdaq Marketplace Rule 5810(c)(3)(A), the Company had a period of 180 calendar days from July 11, 2024, or until January 7, 2025, to regain compliance with the Minimum Bid Price Requirement. On January 8, 2025, the Company received a letter from the Staff indicating the Company's continued non-compliance with the Minimum Bid Price Requirement. The letter further informed the Company that the Company's common stock would be delisted from The Nasdaq Capital Market unless the Company appeals the Staff's delisting determination by requesting a hearing before the Nasdaq Hearings Panel (the Panel"). The Company's request for a hearing will stay any further delisting action by the Staff pending the ultimate outcome of the hearing. The Company's common stock will remain listed and eligible for trading on Nasdaq at least pending the ultimate conclusion of the hearing process. The Company intends to timely request a hearing before the Panel to appeal the determination by the Staff, and to present its plan to regain and sustain compliance with the Minimum Bid Price Requirement. There can be no assurance that the Company will ultimately regain compliance and remain listed on Nasdaq. Announcement • Dec 19
NeuroOne Medical Technologies Corporation Auditor Raises 'Going Concern' Doubt NeuroOne Medical Technologies Corporation filed its Annual on Dec 17, 2024 for the period ending Sep 30, 2024. In this report its auditor, Baker Tilly, gave an unqualified opinion expressing doubt that the company can continue as a going concern. Reported Earnings • Dec 18
Full year 2024 earnings released: US$0.46 loss per share (vs US$0.65 loss in FY 2023) Full year 2024 results: US$0.46 loss per share. Revenue: US$3.45m (up 1.3% from FY 2023). Net loss: US$12.3m (loss widened 3.9% from FY 2023). Announcement • Dec 04
NeuroOne Medical Technologies Corporation to Report Q4, 2024 Results on Dec 17, 2024 NeuroOne Medical Technologies Corporation announced that they will report Q4, 2024 results Pre-Market on Dec 17, 2024 Reported Earnings • Aug 15
Third quarter 2024 earnings released: US$0.10 loss per share (vs US$0.20 loss in 3Q 2023) Third quarter 2024 results: US$0.10 loss per share (improved from US$0.20 loss in 3Q 2023). Revenue: US$825.8k (up 31% from 3Q 2023). Net loss: US$2.77m (loss narrowed 20% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 43% per year, which means it is significantly lagging earnings. Announcement • Aug 12
NeuroOne Medical Technologies Corporation to Report Q3, 2024 Results on Aug 14, 2024 NeuroOne Medical Technologies Corporation announced that they will report Q3, 2024 results on Aug 14, 2024 Announcement • Aug 06
NeuroOne Medical Technologies Corporation announced that it has received $2.650001 million in funding NeuroOne Medical Technologies Corporation announced a private placement that it has issued an aggregate of 2,944,446 shares of the Company’s common stock and warrants to purchase an aggregate of 2,208,338 shares of common stock, at a purchase price of $0.90 per unit for the gross proceeds of $2,650,001 on August 5, 2024. Each unit consisted of one share of common stock and a warrant to purchase 0.75 shares of common stock. The warrants have an exercise price of $1.19 per share of common stock, and are exercisable for a period of three years from the date of issuance. Investors included current institutional investors and insiders. The securities issued and sold in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (“SEC”) or an applicable exemption from such registration requirements. Announcement • Jul 14
NeuroOne Medical Technologies Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement On July 11, 2024, NeuroOne Medical Technologies Corporation (the Company") received a letter (the Notice") from the Listing Qualifications Department (the Staff") of the Nasdaq Stock Market (Nasdaq") notifying the Company that because the closing bid price of the Company's common stock was below $1.00 per share for the prior 30 consecutive business days, the Company is not in compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market, as set in Nasdaq Marketplace Rule 5550(a)(2) (the Minimum Bid Price Requirement"). In accordance with Nasdaq Marketplace Rule 5810(c)(3)(A), the Company has a period of 180 calendar days from July 11, 2024, or until January 7, 2025, to regain compliance with the Minimum Bid Price Requirement. If at any time before January 7, 2025, the closing bid price of the Company's common stock closes at or above $1.00 per share for a minimum of 10 consecutive business days (which number days may be extended by Nasdaq), Nasdaq will provide written notification that the Company has achieved compliance with the Minimum Bid Price Requirement, and the matter would be resolved. The Notice also disclosed that in the event the Company does not regain compliance with the Rule by January 7, 2025, the Company may be eligible for additional time. To qualify for additional time, the Company would be required to meet the applicable market value of publicly held shares requirement for continued listing and all other applicable standards for initial listing on The Nasdaq Capital Market, with the exception of the bid price requirement, and would need to provide written notice of its intention to cure the deficiency during the second compliance period. If the Company meets these requirements, Nasdaq will inform the Company that it has been granted an additional 180 calendar days. However, if it appears to the Staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice that the Company's securities will be subject to delisting. The Company intends to continue actively monitoring the closing bid price for the Company's common stock between now and January 7, 2025, and will consider available options to resolve the deficiency and regain compliance with the Minimum Bid Price Requirement. If the Company does not regain compliance within the allotted compliance period, including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company's common stock will be subject to delisting. The Company would then be entitled to appeal that determination to a Nasdaq hearings panel. There can be no assurance that the Company will regain compliance with the Minimum Bid Price Requirement during the 180-day compliance period, secure a second period of 180 calendar days to regain compliance, or maintain compliance with the other Nasdaq listing requirements. Board Change • Jul 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. Member of Scientific Advisory Board Bob Gross was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Announcement • Jun 25
NeuroOne® Announces First in Human Ablations Completed with OneRF™ Ablation System NeuroOne Medical Technologies Corporation announced that the OneRF Ablation System was recently used at a prestigious hospital located in Jacksonville, Florida to successfully complete five ablations in one patient. The patient was suffering from multifocal epilepsy, a condition whereby seizures are triggered from multiple areas of the brain. In this procedure, ten Evo® sEEG electrodes, were placed in various locations of the patient’s brain. Four electrodes identified problematic areas of the brain that were triggering seizures. Ablations were performed at the targeted areas using the temperature control safety feature, and two of these ablations occurred at different contacts on one electrode. Using the same electrodes, the successful ablations were confirmed by post ablation sEEG recordings demonstrating lack of brain activity at the point of tissue ablation. The procedure was performed at the patient’s bedside saving both the time and cost of having to conduct the procedure in an operating room. The OneRF™ Ablation System is NeuroOne’s first device with a therapeutic indication and its third FDA 510(k)-cleared device. NeuroOne now boasts a full line of thin film electrode technology to address patients requiring diagnostic brain mapping procedures as well as RF ablation using the same sEEG electrode. In addition to the OneRF™ Ablation System, NeuroOne’s other FDA-cleared devices include the Evo® cortical and sEEG electrode product lines which are used primarily for stimulation, recording and monitoring of electrical activity in the brain for less than 30 days. NeuroOne estimates the current brain ablation market to be at least $100 million worldwide and growing rapidly, with the potential to grow multifold based on large addressable patient populations with unmet clinical needs. Announcement • Jun 21
Neuroone Medical Technologies Corporation Receives Approval of ICD-10 Procedure Code for sEEG RF Ablation NeuroOne Medical Technologies Corporation announced that the Centers for Medicare and Medicaid Services (CMS) has approved and granted a new ICD-10-PCS (International Classification of Diseases, 10th Revision, Procedure Coding System) code for the OneRF Ablation procedure. The new code is 00503Z4 Construction of Brain Using Stereoelectroencephalographic Radiofrequency Ablation, Percutaneous Approach. This code allows hospital reporting of inpatient procedures that are performed using the OneRF Ablation system, which has FDA 510(k) clearance for creation of radiofrequency ("RF") lesions in nervous tissue for functional surgical procedures. ICD-10-PCC codes play a critical role in the healthcare system, ensuring efficient and accurate documentation, billing, and analysis. The code goes into effect beginning October 1, 2024. The OneRF Ablation System is NeuroOne's first device with a therapeutic indication and its third FDA 510(k) -cleared device. NeuroOne now boasts a full line of thin film electrode technology to address patients requiring diagnostic brain mapping procedures as well as RF ablation using the same sEEG electrode. In addition to the OneRF Ablation System, NeuroOne's other FDA-cleared devices include the Evo®? cortical and sEEG electrode product lines which are used primarily for stimulation, recording and monitoring of electrical activity in the brain for less than 30 days. NeuroOne estimates the current brain ablation market to be at least $100 million worldwide and growing rapidly, with the potential to grow multifold based on large addressable patient populations with unmet clinical needs. Reported Earnings • May 16
Second quarter 2024 earnings released: US$0.11 loss per share (vs US$0.21 loss in 2Q 2023) Second quarter 2024 results: US$0.11 loss per share (improved from US$0.21 loss in 2Q 2023). Revenue: US$1.38m (up 195% from 2Q 2023). Net loss: US$2.86m (loss narrowed 19% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings. Announcement • May 12
NeuroOne Medical Technologies Corporation to Report Q2, 2024 Results on May 14, 2024 NeuroOne Medical Technologies Corporation announced that they will report Q2, 2024 results on May 14, 2024 Price Target Changed • Mar 27
Price target decreased by 25% to US$2.00 Down from US$2.67, the current price target is provided by 1 analyst. New target price is 66% above last closing price of US$1.21. Stock is down 22% over the past year. The company is forecast to post a net loss per share of US$0.41 next year compared to a net loss per share of US$0.65 last year. Announcement • Mar 26
NeuroOne Medical Technologies Corporation Initiates Limited Commercial Launch of OneRF Ablation System NeuroOne Medical Technologies Corporation announced that it has initiated a limited commercial launch of its OneRF Ablation System, which has FDA 510(k) clearance for creation of radiofrequency (RF) lesions in nervous tissue for functional neurosurgical procedures. The OneRF Ablation System is NeuroOne’s first device with a therapeutic indication and its third FDA 510(k)-cleared device. NeuroOne now boasts a full line of electrode technology to address patients requiring diagnostic brain mapping procedures as well as RF ablation using the same sEEG electrode. In addition to the OneRF Ablation System, NeuroOne’s other FDA-cleared devices include the Evo cortical and sEEG electrode product lines which are used primarily for recording electrical activity in the brain for less than 30 days. Reported Earnings • Feb 14
First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat First quarter 2024 results: US$0.14 loss per share (further deteriorated from US$0.11 loss in 1Q 2023). Revenue: US$977.6k (down 38% from 1Q 2023). Net loss: US$3.34m (loss widened 93% from 1Q 2023). Revenue is forecast to grow 52% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 53% per year, which means it is significantly lagging earnings. Announcement • Feb 09
NeuroOne Medical Technologies Corporation to Report Q1, 2024 Results on Feb 13, 2024 NeuroOne Medical Technologies Corporation announced that they will report Q1, 2024 results on Feb 13, 2024 Announcement • Jan 30
NeuroOne Medical Technologies Corporation, Annual General Meeting, Mar 14, 2024 NeuroOne Medical Technologies Corporation, Annual General Meeting, Mar 14, 2024, at 09:00 US Eastern Standard Time. Location: 7599 Anagram Dr., Eden Prairie MN 55344 Eden Prairie United States Agenda: To elect the Class I director named in the Proxy Statement to a three-year term; To ratify the appointment of our independent registered public accounting firm for 2024; To approve our named executive officers’ compensation in an advisory vote; To approve whether an advisory vote on the compensation of our named executive officers should occur once every one, two, or three years. Recent Insider Transactions • Dec 27
Chief Operating Officer recently bought US$105k worth of stock On the 21st of December, Christopher Volker bought around 75k shares on-market at roughly US$1.40 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Christopher's only on-market trade for the last 12 months. Recent Insider Transactions Derivative • Dec 24
Co-Founder notifies of intention to sell stock Mark Christianson intends to sell 50k shares in the next 90 days after lodging an Intent To Sell Form on the 21st of December. If the sale is conducted around the recent share price of US$1.38, it would amount to US$69k. Since March 2023, Mark's direct individual holding has increased from 330.22k shares to 331.91k. Company insiders have collectively bought US$9.9k more than they sold, via options and on-market transactions, in the last 12 months. Major Estimate Revision • Dec 22
Consensus revenue estimates decrease by 12%, EPS upgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from US$6.90m to US$6.07m. EPS estimate increased from -US$0.415 to -US$0.405 per share. Medical Equipment industry in the US expected to see average net income growth of 19% next year. Consensus price target of US$2.67 unchanged from last update. Share price fell 9.2% to US$1.39 over the past week. Price Target Changed • Dec 17
Price target increased by 27% to US$2.67 Up from US$2.10, the current price target is an average from 2 analysts. New target price is 74% above last closing price of US$1.53. Stock is down 37% over the past year. The company is forecast to post a net loss per share of US$0.44 next year compared to a net loss per share of US$0.65 last year. Reported Earnings • Dec 15
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2023 results: US$0.65 loss per share (further deteriorated from US$0.63 loss in FY 2022). Revenue: US$3.41m (up 61% from FY 2022). Net loss: US$11.9m (loss widened 19% from FY 2022). Revenue missed analyst estimates by 2.6%. Earnings per share (EPS) exceeded analyst estimates by 6.5%. Revenue is forecast to grow 49% p.a. on average during the next 2 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings. Announcement • Dec 12
NeuroOne Medical Technologies Corporation Receives FDA 510(K) Clearance to Market its OneRF(TM) Ablation System NeuroOne Medical Technologies Corporation announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market its OneRF™ Ablation System for creation of radiofrequency (“RF”) lesions in nervous tissue for functional neurosurgical procedures. The OneRF Ablation System is the Company’s first device with a therapeutic indication and its third FDA 510(k)-cleared device. NeuroOne now boasts a full line of electrode technology to address patients requiring diagnostic brain mapping procedures as well as RF ablation using the same sEEG electrode. In addition to the OneRF Ablation System, NeuroOne’s other FDA-cleared devices include the Evo® cortical and sEEG electrode product lines which are used primarily for recording electrical activity in the brain for less than 30 days. Announcement • Dec 08
NeuroOne Medical Technologies Corporation to Report Q4, 2023 Results on Dec 14, 2023 NeuroOne Medical Technologies Corporation announced that they will report Q4, 2023 results on Dec 14, 2023 Announcement • Nov 18
NeuroOne Medical Technologies Corporation Announces Patent Allowance for Drug Delivery Utilizing a Novel Neural Probe NeuroOne Medical Technologies Corporation announced that, the United States Patent and Tradark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application 16/812,702, titled "Agent-Delivering Neural Probe Devices and Related Systems and Methods," which covers novel electrodes that can operate as a standard neural electrode that also delivers a treatment agent to a target area of the patient's brain. A Notice of Allowance is issued by the USPTO after examination of a patent application and a determination that a patent should be granted from the application. NeuroOne anticipates the issuance of the patent in the coming months. In addition to this allowed patent application, NeuroOne's patent portfolio includes the two other allowed patent applications, one issued U.S. patent, eight pending U.S. applications, and several foreign applications covering a wide variety of thin-film electrode technologies, including both neural and spinal cord electrodes with unique structures that optimize the functionality and minimized profile of those electrodes. Announcement • Nov 15
NeuroOne Medical Technologies Corporation Appoints Christopher R. Volker as Chief Operating Officer NeuroOne Medical Technologies Corporation announced that it has appointed medtech executive Christopher R. Volker as Chief Operating Officer. Mr. Volker joins NeuroOne from Abbott Laboratories which acquired Cardiovascular Systems Inc. in April 2023. Mr. Volker held the role of Vice President and General Manager of International at Cardiovascular Systems Inc., where he had direct responsibility for international commercial expansion, including therapy development and driving sales growth from $0 to over $5 million per quarter. Prior to Cardiovascular Systems Inc., Mr. Volker held executive leadership roles at St. Jude Medical, which was also acquired by Abbott, where he led corporate development, global strategic market research and health economics & reimbursement strategy across all of St. Jude Medical's business units as well as held executive responsibilities for human resources for the Cardiovascular Division. He began his career in healthcare and technology investment banking where he gained expertise in M&A, strategic planning, asset sales, and growth equity investments. Mr. Volker earned a Bachelor of Arts degree from St. John’s University and a Masters of Business Administration degree from the Wharton School of the University of Pennsylvania. Announcement • Nov 08
NeuroOne Medical Technologies Corporation Provides Progress Update on FDA 510(k) Submission for OneRF™? Ablation System NeuroOne Medical Technologies Corporation announced that it has responded to the Food and Drug Administration's (FDA) questions regarding the Company's previous submission of a 510(k) for its OneRF™? Ablation System. The Company expects to receive additional communication back from the FDA in thirty days or less. The OneRF system uses the already implanted sEEG electrodes to record brain activity and allow for ablation of nervous tissue when connected to the Company's proprietary radio frequency (RF) generator. If cleared by the FDA, NeuroOne's OneRF 510(k) submission represents the first step in bringing to market an innovative RF ablation system in the field of neurology and neurosurgery. As the Company's first therapeutic device, OneRF is a combination system that includes both diagnostic and therapeutic capabilities. The system utilizes a customized RF generator with real-time temperature monitoring capabilities, allowing clinicians to have greater control over temperature management during the ablation. Designed to both record brain activity and ablate nervous tissue using the same electrode, the system is designed to offer the potential for a safer clinical option for patients as well as lower costs by reducing the number of invasive procedures and hospital stays for patients. NeuroOne estimates the current brain ablation market to be at least $100 million worldwide and growing rapidly, with the potential to grow multiple fold based on large addressable patient populations with unmet clinical needs. The potential to reduce hospital stays, additional procedures, complications and cost gives confidence that this will have a meaningful impact in the market. Recent Insider Transactions • Sep 15
Chief Financial Officer recently bought US$50k worth of stock On the 13th of September, Ronald McClurg bought around 51k shares on-market at roughly US$0.98 per share. This transaction amounted to 83% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Ronald's only on-market trade for the last 12 months. Major Estimate Revision • Aug 21
Consensus revenue estimates increase by 13%, EPS downgraded The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from US$3.10m to US$3.50m. EPS estimate fell from -US$0.65 to -US$0.695 per share. Medical Equipment industry in the US expected to see average net income growth of 21% next year. Consensus price target down from US$2.63 to US$2.10. Share price fell 7.4% to US$1.01 over the past week. Reported Earnings • Aug 16
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Third quarter 2023 results: US$0.20 loss per share (further deteriorated from US$0.17 loss in 3Q 2022). Revenue: US$629.9k (up US$597.9k from 3Q 2022). Net loss: US$3.47m (loss widened 26% from 3Q 2022). Revenue exceeded analyst estimates by 80%. Earnings per share (EPS) also surpassed analyst estimates by 2.4%. Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings. Announcement • Aug 09
NeuroOne Medical Technologies Corporation to Report Q3, 2023 Results on Aug 14, 2023 NeuroOne Medical Technologies Corporation announced that they will report Q3, 2023 results on Aug 14, 2023 New Risk • Jul 26
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$9.0m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings are forecast to decline by an average of 11% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$13m net loss in 2 years). Shareholders have been diluted in the past year (10% increase in shares outstanding). Revenue is less than US$5m (US$4.1m revenue). Market cap is less than US$100m (US$18.9m market cap). Announcement • Jun 13
NeuroOne Medical Technologies Corporation Submits 510(K) Application to FDA for OneRF™ Ablation System NeuroOne Medical Technologies Corporation announced its submission of a 510(k) application to the U.S. Food and Drug Administration for its OneRF™ Ablation System. This technology uses the already implanted sEEG electrodes to record brain activity and allow for ablation of nervous tissue when connected to a proprietary radio frequency (RF) generator. If cleared by the FDA, NeuroOne’s OneRF 510(k) submission represents the first step in bringing to market an innovative RF ablation system in the field of neurology and neurosurgery. As the Company’s first therapeutic device, OneRF is a combination system that includes both diagnostic and therapeutic capabilities. The system utilizes a customized RF generator with real-time temperature monitoring capabilities, allowing clinicians to have greater control over temperature management during the ablation. Designed to both record brain activity and ablate nervous tissue using the same electrode, the system is designed to offer the potential for a safer clinical option for patients as well as lower costs by reducing the number of invasive procedures and hospital stays for patients. NeuroOne estimates the current brain ablation market to be at least $100M worldwide and growing rapidly, with the potential to grow multiple fold based on large addressable patient populations with unmet clinical needs. NeuroOne anticipates receiving initial feedback from the FDA no later than August 7th, 2023. Announcement • May 18
NeuroOne Medical Technologies Corporation Announces First Clinical Case Using Evo® sEEG Electrode in Robotic Neurosurgery NeuroOne Medical Technologies Corporation announced the first clinical case using the Evo sEEG electrode in robotic neurosurgery. Performed by Dr. William Bingaman at Cleveland Clinic, the procedure was the first to utilize NeuroOne's Evo sEEG electrode, exclusively marketed in the U.S. by Zimmer Biomet, with Zimmer Biomet's ROSA One Brain, a robotic platform that assists surgeons in planning and performing complex minimally invasive neurosurgical procedures. Now that Zimmer Biomet has commenced U.S. distribution of Evo sEEG electrodes, this case study confirms the synergistic use of product with Zimmer Biomet's robotics platform which was the foundation of interest to partner with Zimmer Biomet. The Evo sEEG electrode technology offers stereoelectroencephalography recording, brain stimulation and future development of ablation solutions targeted for patients suffering from multiple neurological conditions. In October 2022, NeuroOne received FDA clearance to market its Evo sEEG electrode Technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation Equipment for the recording, monitoring, & stimulation equipment for the recording, Monitoring, and stimulation of electrical signals at the subsurface level of the brain. Major Estimate Revision • May 18
Consensus revenue estimates increase by 13% The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from US$2.75m to US$3.10m. EPS estimate unchanged at -US$0.65. Medical Equipment industry in the US expected to see average net income growth of 18% next year. Consensus price target of US$2.63 unchanged from last update. Share price fell 3.7% to US$1.30 over the past week. Reported Earnings • May 13
Second quarter 2023 earnings released: US$0.21 loss per share (vs US$0.19 loss in 2Q 2022) Second quarter 2023 results: US$0.21 loss per share (further deteriorated from US$0.19 loss in 2Q 2022). Revenue: US$466.2k (up US$429.6k from 2Q 2022). Net loss: US$3.52m (loss widened 15% from 2Q 2022). Revenue is forecast to grow 43% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings. Announcement • May 12
NeuroOne Medical Technologies Corporation to Report Q2, 2023 Results on May 11, 2023 NeuroOne Medical Technologies Corporation announced that they will report Q2, 2023 results at 4:00 PM, US Eastern Standard Time on May 11, 2023 Major Estimate Revision • Feb 20
Consensus revenue estimates decrease by 41%, EPS upgraded The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from US$4.70m to US$2.75m. EPS estimate increased from -US$0.66 to -US$0.645 per share. Medical Equipment industry in the US expected to see average net income growth of 12% next year. Consensus price target of US$2.63 unchanged from last update. Share price fell 17% to US$1.71 over the past week. Reported Earnings • Feb 14
First quarter 2023 earnings: EPS in line with expectations, revenues disappoint First quarter 2023 results: US$0.11 loss per share (improved from US$0.18 loss in 1Q 2022). Revenue: US$1.57m (up US$1.53m from 1Q 2022). Net loss: US$1.73m (loss narrowed 38% from 1Q 2022). Revenue is forecast to grow 29% p.a. on average during the next 2 years, compared to a 7.5% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings. Announcement • Feb 10
NeuroOne Medical Technologies Corporation to Report Q1, 2023 Results on Feb 14, 2023 NeuroOne Medical Technologies Corporation announced that they will report Q1, 2023 results on Feb 14, 2023 Announcement • Jan 28
NeuroOne Medical Technologies Corporation, Annual General Meeting, Mar 16, 2023 NeuroOne Medical Technologies Corporation, Annual General Meeting, Mar 16, 2023, at 09:00 Central Standard Time. Location: 7599 Anagram Dr., Eden Prairie, MN 55344* Minnesota United States Agenda: To elect the Class III directors named in the Proxy Statement to a three-year term; and to ratify the appointment of independent registered public accounting firm for 2023. Major Estimate Revision • Dec 29
Consensus revenue estimates increase by 154% The consensus outlook for revenues in 2023 has improved. 2023 revenue forecast increased from US$1.85m to US$4.70m. Forecast losses expected to reduce from -US$0.74 to -US$0.66 per share. Medical Equipment industry in the US expected to see average net income growth of 13% next year. Consensus price target of US$2.63 unchanged from last update. Share price fell 17% to US$1.18 over the past week. Announcement • Dec 24
NeuroOne Medical Technologies Corporation Auditor Raises 'Going Concern' Doubt NeuroOne Medical Technologies Corporation filed its 10-K on Dec 22, 2022 for the period ending Sep 30, 2022. In this report its auditor, Baker Tilly, gave an unqualified opinion expressing doubt that the company can continue as a going concern. Reported Earnings • Dec 22
Full year 2022 earnings: EPS and revenues exceed analyst expectations Full year 2022 results: US$0.63 loss per share. Revenue: US$2.12m (up US$1.88m from FY 2021). Net loss: US$10.00m (flat on FY 2021). Revenue exceeded analyst estimates by 12%. Earnings per share (EPS) also surpassed analyst estimates by 3.1%. Revenue is forecast to grow 59% p.a. on average during the next 2 years, compared to a 7.3% growth forecast for the Medical Equipment industry in the US. Announcement • Dec 08
NeuroOne Successfully Completes Feasibility Study with its OneRF Ablation System NeuroOne Medical Technologies Corporation announced that it has successfully completed a feasibility study with its OneRF™ ablation system, a developing technology that utilizes existing implanted sEEG diagnostic electrodes for brain tissue lesioning. The study evaluated the Company's new RF ablation system in an animal model. The study used NeuroOne's FDA cleared sEEG electrodes combined with a proprietary RF generator and a unique temperature control accessory that monitors and maintains the temperature at which the ablation is performed. This allows clinicians to set temperature and time for each ablation. Dr. Van Gompel and his team implanted five sEEG electrodes, performed electrophysiological recordings, and then completed a total of ten RF ablations using different settings for temperature and time. All ablations were confirmed by an MRI scan. As previously reported, NeuroOne is also advancing a pipeline of therapeutic electrode technologies for chronic stimulation use for DBS (deep brain stimulation) and spinal cord stimulation for chronic back pain. These therapeutic electrode technologies represent addressable markets valued between $500 million and $6 billion. Price Target Changed • Nov 16
Price target decreased to US$2.63 Down from US$5.88, the current price target is an average from 2 analysts. New target price is 203% above last closing price of US$0.87. Stock is down 67% over the past year. The company is forecast to post a net loss per share of US$0.65 next year compared to a net loss per share of US$0.93 last year. Announcement • Oct 26
NeuroOne Medical Technologies Corporation Receives U.S. Food and Drug Administration 510(K) Clearance to Market Its Evo sEEG System for Less Than 30 Day Use NeuroOne Medical Technologies Corporation announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market its Evo sEEG Electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain. On August 9, 2022, the Company announced it had resubmitted its 510(k) application to the FDA for less than 30 day use, which included additional biocompatibility testing as requested by the FDA. On October 20, 2022, the Company received an FDA clearance letter stating that the Evo sEEG System is substantially equivalent to the predicate device and may be marketed in the United States. The Evo sEEG System represents the Company's second FDA 510(k) cleared product. NeuroOne now provides a full line of electrode technology to address an estimated worldwide market of $100 million for patients requiring diagnostic brain mapping procedures. As opposed to cortical electrodes, sEEG electrodes provide a similar function at the subsurface level of the brain by using a much less invasive process that does not require removal of the top portion of the patient's skull. sEEG electrodes are the predominant technology used in these procedures due to their less invasive placement and subsurface location. The Company's Evo Cortical and sEEG Electrodes are a portfolio of hi-definition thin film electrodes. Potential advantages include increased signal clarity and reduced noise; better tactile feedback during insertion into brain tissue; and faster order fulfillment due to an automated manufacturing process. As previously reported, NeuroOne is also advancing a pipeline of therapeutic electrode technologies for brain tissue ablation and chronic stimulation use for DBS (deep brain stimulation) and spinal cord stimulation for chronic back pain. These therapeutic electrode technologies represent addressable markets valued between $500 million and $6 billion. Reported Earnings • Aug 12
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Third quarter 2022 results: US$0.17 loss per share (up from US$0.25 loss in 3Q 2021). Net loss: US$2.76m (loss narrowed 6.5% from 3Q 2021). Revenue exceeded analyst estimates by 42%. Earnings per share (EPS) also surpassed analyst estimates by 24%. Over the next year, revenue is forecast to grow 808%, compared to a 6.4% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings. 
